RSLB.F Stock Overview
A medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East.
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 3/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
RaySearch Laboratories AB (publ) Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | SEK 15.62 |
| 52 Week High | SEK 15.62 |
| 52 Week Low | SEK 8.00 |
| Beta | 1.34 |
| 11 Month Change | 7.06% |
| 3 Month Change | n/a |
| 1 Year Change | 95.25% |
| 33 Year Change | 116.19% |
| 5 Year Change | -19.90% |
| Change since IPO | 610.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| RSLB.F | US Healthcare Services | US Market | |
|---|---|---|---|
| 7D | 0% | -2.0% | -0.7% |
| 1Y | 95.3% | -0.7% | 32.5% |
Return vs Industry: RSLB.F exceeded the US Healthcare Services industry which returned -0.7% over the past year.
Return vs Market: RSLB.F exceeded the US Market which returned 32.5% over the past year.
Price Volatility
| RSLB.F volatility | |
|---|---|
| RSLB.F Average Weekly Movement | n/a |
| Healthcare Services Industry Average Movement | 9.2% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: RSLB.F's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: Insufficient data to determine RSLB.F's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| n/a | 411 | Johan Lof | www.raysearchlabs.com |
RaySearch Laboratories AB (publ), a medical technology company, provides software solutions for cancer care in the Americas, Europe, Africa, the Asia-Pacific, and the Middle East. It develops and markets RayStation, a treatment planning system for radiation therapy; RayCare, an oncology information system that manages clinical activities; RayIntelligence, a cloud-based analytics system for monitoring and enhancement of cancer therapy; and RayCommand, a treatment control system that serves as link between the treatment machine and the treatment planning and oncology information systems. The company offers RayPlan, a treatment planning system for supporting a range of treatment planning activities for 3D-CRT, IMRT, VMAT, and electron beam radiation therapy; and µ-RayStation, a software platform for planning and evaluation in small animal irradiation research.
RaySearch Laboratories AB (publ) Fundamentals Summary
| RSLB.F fundamental statistics | |
|---|---|
| Market cap | US$511.66m |
| Earnings (TTM) | US$14.71m |
| Revenue (TTM) | US$109.80m |
34.8x
P/E Ratio4.7x
P/S RatioIs RSLB.F overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| RSLB.F income statement (TTM) | |
|---|---|
| Revenue | SEK 1.13b |
| Cost of Revenue | SEK 107.48m |
| Gross Profit | SEK 1.02b |
| Other Expenses | SEK 869.89m |
| Earnings | SEK 151.22m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
Nov 08, 2024
| Earnings per share (EPS) | 4.41 |
| Gross Margin | 90.48% |
| Net Profit Margin | 13.40% |
| Debt/Equity Ratio | 0% |
How did RSLB.F perform over the long term?
See historical performance and comparison